NeoStem's CEO Interviewed on NBC Affiliate KXAN Austin News
NEW YORK, April 21 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Robin Smith, Chairman and CEO of NeoStem took part in an insightful interview with NBC affiliate, KXAN Austin news.
In connection with the April 15th launch of the newest adult stem cell collection center in the NeoStem network, NeoStem's Chairman and CEO was interviewed on KXAN Austin News at the new state-of-the-art Austin collection center. During the interview, Dr. Smith spoke about the promise of adult stem cell therapy and the important role the Company is playing in that future. The full interview can be viewed by visiting the KXAN Austin news website (http://www.kxan.com/dpp/health/austin-clinic-to-bank-adult-stem-cells ).
"This is an exciting time in the evolution of stem cell-based therapies, and NeoStem is well positioned to offer insight as a leading provider of adult stem cell collection, banking and storage services to the general adult population," commented Dr. Robin Smith, Chairman and CEO of NeoStem, Inc. "We are thrilled to be able to share with the public how they can take steps today to prepare for their future."
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the opinions expressed by management as part of the KXAN interview, the expansion of the collection network and the development of stem cell therapies, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact: NeoStem, Inc. Robin Smith, CEO Phone: +1-212-584-4174 Email: email@example.com Web: http://www.neostem.com CCG Investor Relations, Inc. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: firstname.lastname@example.org Web: http://www.ccgirasia.com Crocker Coulson, President Phone: +1-646-213-1915 Email: email@example.com
SOURCE NeoStem, Inc.